Compare Fulford India with Orchid Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FULFORD INDIA vs ORCHID PHARMA LTD - Comparison Results

FULFORD INDIA     Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FULFORD INDIA ORCHID PHARMA LTD FULFORD INDIA/
ORCHID PHARMA LTD
 
P/E (TTM) x 398.8 -0.5 - View Chart
P/BV x 6.2 0.1 5,276.7% View Chart
Dividend Yield % 0.1 0.0 -  

Financials

 FULFORD INDIA   ORCHID PHARMA LTD
EQUITY SHARE DATA
    FULFORD INDIA
Mar-14
ORCHID PHARMA LTD
Sep-13
FULFORD INDIA/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs942194 485.6%   
Low Rs45035 1,285.7%   
Sales per share (Unadj.) Rs691.4276.5 250.1%  
Earnings per share (Unadj.) Rs11.5-79.2 -14.5%  
Cash flow per share (Unadj.) Rs15.4-43.5 -35.3%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.30-  
Book value per share (Unadj.) Rs380.053.9 704.5%  
Shares outstanding (eoy) m3.9070.45 5.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.00.4 243.1%   
Avg P/E ratio x60.7-1.4 -4,200.9%  
P/CF ratio (eoy) x45.3-2.6 -1,719.6%  
Price / Book Value ratio x1.82.1 86.3%  
Dividend payout %17.40-   
Avg Mkt Cap Rs m2,7148,067 33.7%   
No. of employees `0000.42.8 15.9%   
Total wages/salary Rs m5052,527 20.0%   
Avg. sales/employee Rs Th6,073.06,956.1 87.3%   
Avg. wages/employee Rs Th1,137.4902.5 126.0%   
Avg. net profit/employee Rs Th100.7-1,993.0 -5.1%   
INCOME DATA
Net Sales Rs m2,69619,477 13.8%  
Other income Rs m125407 30.8%   
Total revenues Rs m2,82219,884 14.2%   
Gross profit Rs m-461,103 -4.2%  
Depreciation Rs m152,519 0.6%   
Interest Rs m105,227 0.2%   
Profit before tax Rs m54-6,236 -0.9%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m10-125 -7.7%   
Profit after tax Rs m45-5,580 -0.8%  
Gross profit margin %-1.75.7 -30.4%  
Effective tax rate %17.72.0 880.6%   
Net profit margin %1.7-28.7 -5.8%  
BALANCE SHEET DATA
Current assets Rs m1,73811,014 15.8%   
Current liabilities Rs m54532,060 1.7%   
Net working cap to sales %44.3-108.1 -41.0%  
Current ratio x3.20.3 928.9%  
Inventory Days Days4895 51.1%  
Debtors Days Days434 12.8%  
Net fixed assets Rs m1229,440 0.0%   
Share capital Rs m39705 5.5%   
"Free" reserves Rs m1,4432,043 70.6%   
Net worth Rs m1,4823,800 39.0%   
Long term debt Rs m09,018 0.0%   
Total assets Rs m2,07746,510 4.5%  
Interest coverage x6.7-0.2 -3,477.5%   
Debt to equity ratio x02.4 0.0%  
Sales to assets ratio x1.30.4 310.1%   
Return on assets %2.6-0.8 -343.4%  
Return on equity %3.0-146.9 -2.1%  
Return on capital %4.3-3.7 -115.3%  
Exports to sales %037.9 0.0%   
Imports to sales %24.522.6 108.1%   
Exports (fob) Rs mNA7,378 0.0%   
Imports (cif) Rs m6594,406 15.0%   
Fx inflow Rs m177,513 0.2%   
Fx outflow Rs m6735,649 11.9%   
Net fx Rs m-6561,865 -35.2%   
CASH FLOW
From Operations Rs m901,682 5.4%  
From Investments Rs m105-9,860 -1.1%  
From Financial Activity Rs m-146,644 -0.2%  
Net Cashflow Rs m181-1,535 -11.8%  

Share Holding

Indian Promoters % 0.0 32.3 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 3.8 4.6 82.6%  
FIIs % 0.1 3.3 3.0%  
ADR/GDR % 0.0 4.6 -  
Free float % 21.2 55.3 38.3%  
Shareholders   4,783 84,811 5.6%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FULFORD INDIA With:   SANOFI INDIA  ABBOTT INDIA  PANACEA BIOTECH  WYETH LTD  GSK PHARMA  

Compare FULFORD INDIA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 76 Points Lower; Telecom and Metal Stocks Witness Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their volatile day marginally lower.

Related Views on News

ORCHID PHARMA LTD Announces Quarterly Results (2QFY19); Net Profit Up 67.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8% (Quarterly Result Update)

Aug 24, 2018 | Updated on Aug 24, 2018

For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

How the Modi Government is Helping My Top 7 Stocks(The 5 Minute Wrapup)

Nov 14, 2019

Recent reforms by the Modi government can give a big boost on your stocks, provided you buy the right ones.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FULFORD INDIA SHARE PRICE


Jul 30, 2015 (Close)

TRACK FULFORD INDIA

  • Track your investment in FULFORD INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

FULFORD INDIA - STRIDES PHARMA SCIENCE COMPARISON

COMPARE FULFORD INDIA WITH

MARKET STATS